SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019
16 references·0 citing·48 second hop
Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019 (2023)Comparison of Research Spending on New Dr…Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies (2020)Profitability of Large Pharma…Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)Estimated Research and Develo…Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules (2018)Public R&D Investments and Pr…Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Defining Elements of Value in…The applied value of public investments in biomedical research (2017)The applied value of public i…Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Innovation in the pharmaceuti…From market fixing to market-creating: a new framework for innovation policy (2016)From market fixing to market-…Big names or big ideas: Do peer-review panels select the best science proposals? (2015)Big names or big ideas: Do pe…The risk-reward nexus in the innovation-inequality relationship: who takes the risks? Who gets the rewards? (2013)The risk-reward nexus in the …An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011 (2013)An Improved Approach To Measu…What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation? (2011)What Are The Respective Roles…The Role of Public-Sector Research in the Discovery of Drugs and Vaccines (2011)The Role of Public-Sector Res…The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry (2011)The impact of public basic re…The Economics of Follow-on Drug Research and Development (2004)The Economics of Follow-on Dr…Guidelines for Social Return on Investment (2004)Guidelines for Social Return …Is public R&D a complement or substitute for private R&D? A review of the econometric evidence (2000)Is public R&D a complement or…Economic Welfare and the Allocation of Resources for Invention (1962)The Matthew Effect in Science (1968)The Matthew effect in science. The reward and communication systems of science are considered. (1968)Discretion in Hiring* (2017)The science of science: From the perspective of complex systems (2017)Gender differences in peer review outcomes and manuscript impact at six journals of ecology and evolution (2019)The price of innovation: new estimates of drug development costs (2003)The importance of new companies for drug discovery: origins of a decade of new drugs (2010)US academic drug discovery (2011)The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs (2015)Public sector financial support for late stage discovery of new drugs in the United States: cohort study (2019)Endogenous Technological Change (1989)Endogenous Technological Change (1990)A Model of Growth Through Creative Destruction (1992)A Toolkit of Policies to Promote Innovation (2019)Does Science Advance One Funeral at a Time? (2019)Knowledge Spillovers and Corporate Investment in Scientific Research (2021)Theory of the firm: Managerial behavior, agency costs and ownership structure (1976)Separation of Ownership and Control (1983)Twenty challenges for innovation studies (2016)Assetization (2020)COVID-19 and public-sector capacity (2020)Cost-Effectiveness in Health and Medicine (1996)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Essential medicines for universal health coverage (2016)The High Cost of Prescription Drugs in the United States (2016)Measuring the efficiency of decision making units (1978)Co-Integration and Error Correction: Representation, Estimation, and Testing (1987)Absorptive Capacity: A New Perspective on Learning and Innovation (1990)Mobilizing private finance for low-carbon innovation – A systematic review of barriers and solutions (2017)Closing the green finance gap – A systems perspective (2019)Hedonic Prices and Implicit Markets: Product Differentiation in Pure Competition (1974)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7] (2018)An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2] (2018)The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) (2023)Methods for the Economic Evaluation of Health Care Programmes (2005)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)On the Opportunities and Risks of Foundation Models (2021)Costs of Drug Development and Research and Development Intensity in the US, 2000-2018 (2024)Appropriating the Returns from Industrial Research and Development (1987)National Innovation Systems: A Comparative Analysis (1993)Do R&D tax credits work? Evidence from a panel of countries 1979–1997 (2002)Environmental Policy and Technological Change (2002)The impact of R&D subsidies on firm innovation (2015)Triple Bottom Line: A Business Metaphor for a Social Construct (2006)Developments in Social Impact Measurement in the Third Sector: Scaling Up or Dumbing Down? (2011)Measurement as legitimacy versus legitimacy of measures (2013)
this work references cited by second hop

References

  • 2016Innovation in the pharmaceutical industry: New estimates of R&D costs3,352 cited
  • 2000Is public R&D a complement or substitute for private R&D? A review of the econometric evidence1,638 cited
  • 2020Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-20181,528 cited
  • 2016From market fixing to market-creating: a new framework for innovation policy755 cited
  • 2018Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]544 cited
  • 2018Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules348 cited
  • 2013The risk-reward nexus in the innovation-inequality relationship: who takes the risks? Who gets the rewards?284 cited
  • 2011The Role of Public-Sector Research in the Discovery of Drugs and Vaccines245 cited
  • 2015Big names or big ideas: Do peer-review panels select the best science proposals?225 cited
  • 2004Guidelines for Social Return on Investment217 cited
  • 2011The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry213 cited
  • 2017The applied value of public investments in biomedical research192 cited
  • 2011What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?190 cited
  • 2004The Economics of Follow-on Drug Research and Development

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

189 cited
  • 2020Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies176 cited
  • 2013An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011138 cited
  • Cited by

    No citing works inside the corpus for this window.